APOC3, coronary disease, and complexities of Mendelian randomization.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25185943.
- Also identified by DOI 10.1016/j.cmet.2014.08.007 and PMC identifier 4235518.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.
Medical subject headings
- Apolipoprotein C-III
- Coronary Disease
- Ischemia
- Mutation
- Myocardial Ischemia
- Triglycerides